Cannabit
The conversation around legalizing psychedelics for therapeutic use is heating up! Half of the cannabis consumers in our survey support access to substances like LSD, psilocybin, MDMA, and Ketamine for therapeutic use, while 21% do not, and 28% are still deciding. This progressive stance is particularly intriguing given that 60% of these respondents have never tried these substances themselves.
This data challenges the stereotype that just because someone uses cannabis, they use other substances as well. Instead, it reveals broader, more principled support for drug policy reform. Much like the movement that propelled support for medical cannabis legalization, this viewpoint underscores a belief in access for people who could potentially benefit from these substances, even among those who do not use them personally. This support extends beyond personal experience. It mirrors the earlier phases of the medical cannabis legalization movement, where both patients and non-patients united in the belief that people should have access to medical cannabis if their doctor believes it could provide relief. It’s a mature, nuanced perspective that prioritizes potential therapeutic benefits over prohibition.
As society continues to grapple with drug policy, the voices of these cannabis consumers offer valuable insights. Support for access to psychedelics for therapeutic use, even among non-consumers, indicates a growing recognition of the medical potential of these substances and a desire for progressive, informed drug policies.
Are you looking for more detailed cannabis insights? Contact New Frontier Data to discover how we can provide customized research tailored to your needs.
